Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Outubro 2023 - 8:00AM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the
“Company”), a leading microbiome therapeutics company, today
announced that on October 4, 2023, the Compensation and Talent
Committee of Seres’ board of directors granted inducement equity
grants covering an aggregate of 3,000 shares of its common stock to
two new employees, consisting of stock options to purchase an
aggregate of 1,500 shares of common stock and restricted stock
units (“RSUs”), covering an aggregate of 1,500 shares of its common
stock.
These stock options and inducement RSUs are subject to the terms
of the Seres Therapeutics, Inc. 2022 Employment Inducement Award
Plan (the “Inducement Plan”).
The Inducement Plan is used exclusively for the grant of equity
awards to individuals as an inducement material to their entering
into employment with Seres pursuant to Nasdaq Listing Rule
5635(c)(4). The Inducement Plan was adopted by Seres’ board of
directors in December 2022.
The stock options have an exercise price of $2.00 per share.
Each option will vest as to 25% of the total number of shares
subject to the option on the first anniversary of the applicable
individual’s date of hire and as to 6.25% of the total number of
shares subject to the option upon a completion of each three full
months of service to the Company thereafter. The RSUs vest as to
25% of an award on the first 15th day of a calendar month that
immediately follows the first anniversary of the applicable
individual’s date of hire and as to an additional 6.25% of the
award, upon completion of each three full months of service to the
Company thereafter.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage
company developing novel microbiome therapeutics for serious
diseases. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231006105161/en/
IR and PR Kevin Mannix kmannix@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Seres Therapeutics (NASDAQ:MCRB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024